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to be 194.4 compared with 194.1 for the Alendronic acid group, which resulted 
in a difference of 0.33 QALYs. The total costs for the Zoledronic acid group and 
Alendronic acid group were LE 215,232 and LE 215,087 respectively. These costs 
yielded an ICER of LE 435 for the Zoledronic acid group. The odds ratio of zoledronic 
acid on vertebral & non-vertebral fractures was found to have the greatest impact 
on the results. ConClusions: Compared with our willingness-to-pay thresh-
old stated by world health organization for middle and lower income countries, 
Zoledronic acid is cost-effective; and most likely to result in an ICER lower than 
the threshold limit. Thus, the new treatment (Zoledronic acid) should be recom-
mended in the Ministry of health list.
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CoSt-EffECtivEnESS AnAlySiS of CAnACinuMAb in thE trEAtMEnt of 
PAtiEntS SuffEring froM SyStEMiC JuvEnilE idioPAthiC ArthritiS in 
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objeCtives: To conduct the cost-effectiveness analysis (CEA) of canakinumab 
treatment group versus tocilizumab treatment group with systemic juvenile idi-
opathic arthritis (SJIA). Methods: CEA was used to compare canakinumab treat-
ment of patient group with previous inadequate response to tocilizumab versus 
tocilizumab treatment patient group which was subsequently switched to canaki-
numab. This analysis based on comparing treatments with usage of American 
College Rheumatology (ACR) criteria: ACR 30, 50, 70, 90 according to data of real 
clinical practice that were estimated within one year of therapy. Cost structure 
included following: drug treatment and administration costs, inpatient and out-
patient visits, correction of adverse events and required monitoring laboratory 
tests. Results: Cost-effectiveness ratios (CER) of tocilizumab and canakinumab 
treatment group was estimated for ACR 30 as 4,043,444 RUB/66,173 EUR and 
15,813,187 RUB/258,791 EUR, respectively; for ACR 50 as 4,043,444 RUB/66,173 EUR 
and 17,570,208 RUB/287,546 EUR, respectively; for ACR 70 as 7,188,345 RUB/ 117,641 
EUR and 19,284,375 RUB/315,599 EUR, respectively; ACR90 as 25,878,040 RUB/ 423,508 
EUR and 21,962,760 RUB/359,432 EUR, respectively. ConClusions: According to 
results of CEA costs per unit of effectiveness for treatment with canakinumab were 
higher in most cases. However, CER for ACR 90 as more effectiveness criteria was 
lower for canakinumab treatment group then in tocilizumab treatment patient 
group who were subsequently switched on canakinumab. It was determined that 
treatment with canakinumab was dominant method in comparison with tocili-
zumab treatment for ACR 90 criteria.
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PErSPECtivE of thE brAziliAn hEAlthCArE SyStEM
Ferreira CN, Rufino CS, Santana CF, Dulcine M
Pfizer, São Paulo, Brazil
objeCtives: To assess the cost-effectiveness ratio of tofacitinib when compared 
to alternative treatment strategies currently available for moderate to severe 
rheumatoid arthritis (RA) from the perspective of the Brazilian healthcare sys-
tem. Methods: A patient-level microsimulation model with a six-month length 
has been developed to measure the lifetime cost and quality-adjusted life-years 
(QALY) associated with RA treatment and disease progression. Patients’ outcome 
ranged based on the HAQ score. In the model, only severe adverse events were taken 
into consideration. The model compared treatment sequence with tofacitinibe with 
a comparator sequence without tofacitinibe in the patient care pathway following 
the 2014 Brazilian Therapeutic Guidelines for RA. The costs related to drug treat-
ment and to patient follow-up were taken into consideration. For such, the list price 
published by the Brazilian agency was used. Monitoring standards were defined 
by specialists and funded by using the list of procedures, orthoses, and prostheses 
from SUS [Brazilian Unified Health System] (SIGTAP) and the website for healthcare 
information (TABNET) from the Ministry of Health. The probability sensitivity analy-
sis was calculated having 50 first-order iterations and 500 second-order iterations, 
thus yielding a total of 25,000 iterations. An amount of BRL 81,667 was adopted 
as a limit of willingness to pay – equivalent to three times the national GDP per 
capita (2014). Results: In all scenarios, the treatment arm including tofacitinibe 
was shown to be dominant with lower costs and greater effectiveness – saving 
up to BRL 77,271.97. The probability sensitivity analysis (PSA) was also completed 
showing that tofacitinibe likely to be 52% more effective, 92% more economical and 
87% more cost-effective for one of the scenarios. ConClusions: The inclusion of 
tofacitinibe into the treatment strategy for moderate to severe RA is a dominant 
strategy for Brazilian healthcare system. These results were shown to be robust 
after completing PSA.
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objeCtives: To evaluate certolizumab pegol (CZP) relative to the other anti-TNFs, 
etanercept, infliximab, adalimumab and golimumab, and standard of care (SoC), 
among patients with active psoriatic arthritis (PsA), previously unresponsive to 
conventional disease-modifying antirheumatic drugs (cDMARD). Methods: A 
Markov model was used to simulate the lifetime progression of active PsA patients 
from treatment onset onwards. The model assumed that non-responders stop 
treatment and move to SoC. At treatment initiation, a 12- or 24-week treatment 
response assessment period was assumed. Long-term treatment withdrawal and 
patient mortality rates were obtained from the literature. SoC was defined as a 
mix of cDMARDs based on expert advice. Clinical efficacy was modeled in terms 
These results are in line with the Spanish clinical guidelines for RA which recom-
mend the use of tumor necrosis factor inhibitors as first-line treatment after failure 
with disease-modifying antirheumatic drugs.
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objeCtives: This analysis was designed to estimate the budget impact following 
the introduction of apremilast in the treatment of active psoriatic arthritis (PsA) for 
adult patients who have failed to respond to or are intolerant of disease-modifying 
antirheumatic drugs (DMARDs) in Spain. Methods: A budget impact model was 
developed to estimate healthcare costs for adults with PsA during a 3-year period 
from the NHS perspective. Target population was defined based on epidemiologi-
cal criteria; PsA prevalence (0.2%) and proportion of patients on biologic treatment 
(13.5%) were applied to national adult population statistics. Addition of apremilast 
to the therapeutic arsenal (adalimumab, etanercept, golimumab, infliximab, usteki-
numab) was explored. From the annual eligible population of PsA patients (N= 8,122), 
5% (n= 406), 11% (n= 893), and 18% (n= 1,462) were assumed to be treated with apre-
milast for the first, second, and third year, respectively. A local expert panel provided 
detailed resource consumption information. Total cost included drug acquisition 
based on drug doses from the summaries of product characteristics (ex-factory 
price with mandatory deduction), administration (parenteral drugs), and monitor-
ing costs. Unitary costs (€ , 2014) were obtained from national databases. Results: 
The total budget for the scenario without apremilast was € 101,104,837, € 101,082,349, 
and € 100,875,977 in the first, second, and third year, respectively. The pharmaceu-
tical cost represented 95% of this total cost. Following apremilast introduction, 
total budgets were reduced by € 1,244,342, € 2,735,080, and € 4,438,438 in the first, 
second, and third year, respectively. Incremental costs per patient comparing the 
scenario with apremilast vs. the scenario without apremilast were € −153.21 (−1.23%), 
€ −336.77 (−2.71%), and € −546.50 (−4.40%) in the first, second, and third year, respec-
tively. ConClusions: Apremilast treatment for PsA patients who have failed to 
respond to or are intolerant of DMARDs would imply a budget impact decrease on 
overall healthcare expenditure for the NHS.
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objeCtives: To determine the cost-effectiveness of apremilast for the treatment of 
active psoriatic arthritis for adult patients who failed to respond to or are intoler-
ant to disease-modifying antirheumatic drugs in Italy. Methods: A Markov state-
transition cohort model was adapted to the Italian setting to compare costs and 
quality-adjusted life-years (QALYs) from 2 treatment sequences: apremilast, adali-
mumab, etanercept, infliximab, and best supportive care (BSC) versus adalimumab, 
etanercept, infliximab, and BSC. The analysis time horizon was 40 years using a 
28-day cycle length. The perspective of the Italian National Health Service (NHS) was 
chosen. Treatment efficacy data (based on American College of Rheumatology [ACR] 
20 criteria and Psoriasis Area and Severity Index [PASI] 50/75/90 response rates) were 
derived from a network meta-analysis including 13 clinical trials. Resource use 
and unit costs were derived from Italian standard sources. Frequency of screening 
and testing for each treatment was derived from real-world data. Utility weights 
associated with PASI states were derived from a published study. A 3% discount rate 
was applied to costs and benefits. Both deterministic and probabilistic sensitivity 
analyses (PSA) were performed. Results: In the base case, the sequence including 
apremilast resulted in an incremental cost per QALY gained of € 32,263. Specifically, 
there was an increase of € 13,511 (€ 182,209 vs € 168,699) with an incremental gain of 
QALYs of 0.42 (9.57 vs 9.15) over 40 years. Base-case results were robust regarding 
changes in cost and efficacy data. Results were more sensitive to changes in utility 
weights, discount rates, and time horizon. The PSA confirmed that the apremilast 
sequence was cost-effective in the majority of the simulations at a willingness to 
pay of € 50,000 per QALY. ConClusions: This analysis suggests that the use of 
apremilast for the treatment of psoriatic arthritis may represent a cost-effective 
option for the Italian NHS.
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objeCtives: To evaluate from the Ministry of Health perspective, over a five-year 
period, the cost-effectiveness of using zoledronic acid 5mg compared to that of 
alendronic acid in the treatment of osteoporosis in postmenopausal Egyptian 
patients. Methods: A Markov model with five mutually exclusive health states 
(Well, hip fracture, spine (vertebral) fracture, wrist (non-vertebral) fracture, and 
death) was developed.The transition probabilities between the health states 
were derived from a previously published source. Health state utilities and major 
adverse events were obtained from published sources. Direct medical costs were 
obtained from the Ministry of health list. Costs and effects were discounted at 
3.5% annually. One way sensitivity analyses were conducted. Results: Across the 
overall population, the total QALYs of the Zoledronic acid group were estimated 
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objeCtives: Osteoarthritis (OA) is the most common and costly bone and joint 
disease in the elderly. Recently, viscosupplementation, an intra-articular injection 
of artificial joint fluid in order to restore rheological properties affecting lubrica-
tion and shock absorption, has introduced as an alternative conservative treat-
ment. To assess the effectiveness and cost-effectiveness of Hylan G-F 20 (Hylan) as 
a substitute for existing treatments for pain due to OA of the knee, other viscosup-
plementation devices, and/or as an adjunct to conventional therapy. Methods: A 
Markov microsimulation model was developed to define a treatment pathway for 
OA of the knee, illustrate the current costs of treating patients with the condition, 
and demonstrate the potential savings associated with introduction of Hylan. 
A hypothetical cohort of patients categorized as having 2-3 or 4 degree of OA of 
the knee was followed over a 30-month time period. Results: When compar-
ing intra-articular administration of Hylan, the use of NSAIDs and intra-articular 
administration of corticosteroids (GCS), rirost costs compared with the strategy 
of NSAIDs amounted to $192 rate per 1 patient. This increase in efficiency of 20% 
in favor of Hylan. Accordingly, the ratio ICER was $979 per patient, which is much 
below the threshold of “society’s willingness to pay.” Markov cycle for patients 
with OA of the knee of 4 degrees showed that use of Hylan is more effective in the 
end point of modeling the effectiveness of this strategy was 12% (compared to 
0% in the policies of NSAIDs and corticosteroids). We calculated the total cost of 
the budget in the application of NSAIDs, GCS, and Hylan, after calculations found 
that the use of Gilan can save significant budget funds - up to $954582 (for 1,000 
patients). ConClusions: Hylan may delay the need for joint replacement in 
patients with OA of 4 degrees, suggest its use is justified from a clinical and eco-
nomic standpoint as compared to the consideration of other treatment strategies.
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objeCtives: Failed back surgery syndrome (FBSS) represents one main cause 
of chronic neuropathic or mixed pain and functional disability. Results from 
previous clinical trials and from the PRECISE naturalistic study [Zucco et al, 
Neuromodulation, 2015] show that Spinal Cord Stimulation (SCS) provides pain 
relief and improves patients’ health. Our current aim is to understand the rela-
tionship between pain intensity, functional disability, and overall Health-Related 
Quality-of-life (HRQoL). Methods: At recruitment (before SCS) and every 6 
months for 2 years after SCS a battery of questionnaires/tests were completed: 
EQ-5D-3L and SF-36 for HRQoL, the Numerical Rating Scale (NRS) to measure pain 
intensity, and the Oswestry Disability Index (ODI) to measure disability/functional 
capability. Statistical tests were conducted to compare the HRQoL levels (using the 
EQ-5D utility index, the EQ-VAS, the SF-36 Physical Component Summary (PCS) 
and Mental Component Summary (MCS) index), NRS and ODI at baseline with 
those measured during the observational period. Multilevel regression analyses 
were conducted to investigate the association between the HRQOL indexes and 
the NRS and ODI indexes, on adjusting for: age, gender, previous surgery, educa-
tion, baseline level of the dependent variable, and time of assessment. Results: 
Eighty patients (40% male, mean age= 58 years) participated. Significant improve-
ments (p< 0.001) in pain intensity, functional capability and HRQoL were reached 
after 6 months from SCS and maintained or further improved until the end of 
the observational period. According to the regression models, every HRQoL index 
was significantly associated (p< 0.001) with both the NRS and the ODI indexes 
at any time of assessment. ConClusions: Our results suggest that in a 2-year 
observational period, SCS+CMM treatment reduces significantly pain intensity and 
functional disability in patients with FBSS, with significant repercussions on their 
general HRQOL. Furthermore, our results suggest the HRQoL instruments used in 
this study are valid to assess overall patients’ health and treatment outcomes.
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objeCtives: Effective but expensive (approximately € 14,000 per year) tumor 
necrosis factor inhibiting drugs (TNFi) are used for the treatment of several chronic 
inflammatory diseases including rheumatoid arthritis (RA). A proven dose reduc-
tion strategy in RA patients could result in substantial cost savings. It may however 
also lead to a loss of quality of life as a result of flares induced by dose reduction 
attempts. If this loss is compensated with large cost saving, we might still consider 
the intervention cost-effective. Methods: a pre-planned cost-effectiveness analy-
sis of the DRESS study, a randomised controlled, non-inferiority trial comparing a 
disease activity guided dose optimisation strategy with usual care in patients with 
RA and low disease activity using TNFi. Total health care costs were measured and 
quality adjusted life years (QALY) were based on EQ5d utilities. Decremental cost-
effectiveness ratio and incremental net monetary benefit (iNMB) were determined. 
of the Psoriatic Arthritis Response Criteria, Health Assessment Questionnaire 
and Psoriasis Area and Severity Index data, synthesized from published clini-
cal trials via a Bayesian network meta-analysis. Following a payer perspective, 
direct costs relating to drug acquisition, administration, monitoring and overall 
patient management were considered (2015). Results: All anti-TNF therapies 
yielded greater improvements in the aforementioned efficacy outcomes and in 
terms of quality-adjusted life years (QALYs) compared to SoC. The incremental 
cost per QALY gained of CZP relative to SoC was € 16,539 and € 20,714 at 12- and 
24-week response assessment period respectively, which is below the established 
willingness-to-pay threshold of € 34,000. Between the anti-TNFs, efficacy differ-
ences did not reach statistical significance. In terms of the mean lifetime patient 
cost, it ranged from € 61,469 for CZP to € 86,632 for infliximab, assuming a 12-week 
response assessment period. Similarly, at the alternative assessment period sce-
nario, it ranged from € 66,401 and € 67,499 for golimumab and CZP respectively, to 
€ 83,483 for infliximab. ConClusions: CZP was found to be cost-effective relative 
to SoC and as effective in terms of efficacy and less costly, i.e. dominant, compared 
to most other licensed anti-TNF agents in Greece.
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objeCtives: A Telerehabilitation service following Total Knee Replacement (TKR) 
has been shown to be not inferior to standard rehabilitation (SR) in recovering the 
active knee flexion range of motion (ROM) in patients who had not complication 
related to TKR surgery. However, little is known about its cost-effectiveness. The 
objective of this economic evaluation was to assess cost-effectiveness of telereha-
bilitation versus SR. Methods: A Markov model was employed to simulate the 
natural progression of TKR, assuming telerehabilitation does not influence this. 
The revision risk was calculated from patient-level data (multicentre KAT trial) 
employing a parametric model including established prognostic factors. The others 
state-transition probabilities and treatments effects were obtained from published 
literature. Rehabilitation and transportation costs were assessed adopting Ita-
NHS perspective employing Italian tariffs. The patients without complications 
followed the TR-SR programme receiving half of the sessions in SR and half in 
telerehabilitation regime. Patients with any complication followed the SR receiv-
ing face-to-face sessions. Results were adjusted applying an annual discount rate 
of 3% and half-cycle correction. Probabilistic sensitivity analysis (PSA) described 
the parameters uncertainty. Results: A cohort of 1000 patients with the features 
of KAT trial population (70 years old, 44% male and 19% had any complication 
related to the surgery) were first assigned to SR then to TR -SR. The mean (SE) 
lifetime healthcare cost in SR arm were € 1,033.81 (€ 21.97) and € 818.44 (€ 13.82) for 
telerehabilitation (mean±95%CI difference -215.33±€ 10.64). Mean (SE) ROM was 
16.68 (0.04) in SR programme and 18.84 (0.04) in telerehabilitation programme 
(mean±95%CI difference 2.16±0.09). The probability that telerehabilitation is cost-
saving (WTP:€ 0) is 92%. ConClusions: Adopting the healthcare provider per-
spective, TR-SR seems cost-effective when compared to a SR programme. Further 
sensitivity analyses are required to relax the model assumptions and to assess 
the robustness of the model.
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objeCtives: This study aims to evaluate the cost-effectiveness of Tocilizumab-
based-regimen and other four biologic-based-regimens for the treatments of 
DMARD-IR rheumatoid arthritis patients in China. Methods: A network meta-
analysis (NMA) was performed to combine and compare ACR response rates across 
all relevant RCT evidences. The real-world treatment fees, including drugs, monitor-
ing and administration fees, were collected through expert interviews in Beijing, 
Shanghai, Guangzhou and Chengdu city. All Patient-Assistant-Programs were con-
sidered in drug-cost calculation. The cost-effectiveness analysis was conducted to 
evaluate average costs per ACR20/50/70 response among five regimens. Results: 
The NMA analysis included 28 eligible RCTs. The results indicated that ACR20/50/70 
response rates of Tocilizumab-based-regimen were 74%, 56% and 28% respectively. 
While the ACR20/50/70 response rates of other four regimens (Adalimumab, 
Infliximab, Etanercept and Etanercept-NCB (Non-Comparable-Biologics)) were 77%, 
55% and 19% respectively. The total treatment fees of these five regimens within 
48-weeks were calculated to be RMB 87,384, RMB 113,162, RMB 82,386, RMB 154,894 
and RMB 93,582. The cost-effectiveness results demonstrated that, compared 
with other four regimens, Tocilizumab-regimen cost the average of RMB 312,087 
(USD50,336) to achieve an ACR70 response. It cost RMB 118,087 (USD19,046) per 
ACR20 response and RMB 156,044 (USD25,168) per ACR50 response, which were 
comparable with Infliximab-regimen, but less than others. Tocilizumab could save 
costs ranged from RMB 3,449 (USD556) to RMB 503,147 (USD81,152) in order to fully 
achieve ACR20/50/70 response rates compared with other regimens. ConClusions: 
The study demonstrated that, compared with other available biologicals in China, 
Tocilizumab-regimen was the most cost-effective to achieve ultimate ACR70 
response for DMARD-IR rheumatoid arthritis patients. It also suggested that it had 
similar cost-effectiveness results to Infliximab to achieve ACR20/50 responses.
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